| General Information of Drug Metabolite (DM) (ID: DM019433) |
| DM Name |
AG met
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
UDP-glucuronosyltransferase 1A1 (UGT1A1)
|
DME0004
|
| Unclear - Unclear |
Fevipiprant
|
[1] , [2] |
|
UDP-glucuronosyltransferase 1A3 (UGT1A3)
|
DME0041
|
| Unclear - Unclear |
Fevipiprant
|
[1] , [2] |
|
UDP-glucuronosyltransferase 2B17 (UGT2B17)
|
DME0066
|
| Unclear - Unclear |
Fevipiprant
|
[1] , [2] |
|
UDP-glucuronosyltransferase 2B7 (UGT2B7)
|
DME0040
|
| Unclear - Unclear |
Fevipiprant
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Fevipiprant |
DR3436
|
Phase 3 |
Asthma |
|
|
| References |
| 1 |
Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator. Drug Metab Dispos. 2021 May;49(5):389-394. doi: 10.1124/dmd.120.000273.
|
| 2 |
Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
